Literature DB >> 6352237

Guanabenz. A review of its pharmacodynamic properties and therapeutic efficacy in hypertension.

B Holmes, R N Brogden, R C Heel, T M Speight, G S Avery.   

Abstract

Guanabenz is an orally active central alpha 2-adrenoceptor agonist. Its antihypertensive action is thought to result from a decrease in sympathetic outflow from the brain to the peripheral circulatory system as a result of stimulation of central alpha 2-adrenoceptors. In mild to moderate hypertension it is as effective as methyldopa and clonidine in lowering blood pressure when used as the sole treatment. As with these drugs, guanabenz may be combined with a diuretic to increase its blood pressure-lowering effect. The overall incidence of side effects seen with guanabenz was at least as high as with methyldopa or clonidine, and side effects such as drowsiness or dry mouth have been bothersome enough to lead to discontinuation of guanabenz therapy in some patients. However, particularly troublesome effects such as sodium retention, depression or sexual dysfunction which may occur with methyldopa or clonidine have not been reported with guanabenz.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6352237     DOI: 10.2165/00003495-198326030-00003

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  32 in total

1.  Studies on the centrally mediated hypotensive activity of guanabenz.

Authors:  T Baum; A T Shropshire
Journal:  Eur J Pharmacol       Date:  1976-05       Impact factor: 4.432

2.  Evaluation of the efficacy and safety of guanabenz versus clonidine.

Authors:  W P Leary; A C Asmal; P C Williams
Journal:  S Afr Med J       Date:  1979-01-20

3.  Comparative antihypertensive effects of guanabenz and clonidine.

Authors:  B R Walker; L E Hare; M W Deitch
Journal:  J Int Med Res       Date:  1982       Impact factor: 1.671

4.  Study of a new antihypertensive (guanabenz).

Authors:  F G McMahon; P A Cole; P W Boyles; S K Vanov
Journal:  Curr Ther Res Clin Exp       Date:  1974-05

5.  Lowering of rat brain 3-methoxy-4-hydroxyphenylethylene glycol sulphate (MOPEG sulphate) concentration by 2,6-dichlorobenzylidene aminoguanidine.

Authors:  R W Fuller; H D Snoddy; W S Marshall
Journal:  J Pharm Pharmacol       Date:  1977-06       Impact factor: 3.765

6.  Evaluation of guanabenz added to hydrochlorothiazide therapy in hypertension.

Authors:  B R Walker; M W Deitch; J A Gold; B A Levey
Journal:  J Int Med Res       Date:  1982       Impact factor: 1.671

7.  Guanabenz in essential hypertension.

Authors:  F G McMahon; J R Ryan; A K Jain; R Vargas; S K Vanov
Journal:  Clin Pharmacol Ther       Date:  1977-03       Impact factor: 6.875

8.  Pharmacokinetic disposition of guanabenz in the rhesus monkey.

Authors:  R H Meacham; S T Chiang; C J Kick; S F Sisenwine; W J Jusko; H W Ruelius
Journal:  Drug Metab Dispos       Date:  1981 Nov-Dec       Impact factor: 3.922

9.  Effect of guanabenz and hydrochlorothiazide on blood pressure and plasma renin activity.

Authors:  O B Holland; C Fairchild; C E Gomez-Sanchez
Journal:  J Clin Pharmacol       Date:  1981-04       Impact factor: 3.126

10.  Comparison of guanabenz and clonidine in hypertensive patients.

Authors:  Y Kluyskens; J Snoeck
Journal:  Curr Med Res Opin       Date:  1980       Impact factor: 2.580

View more
  41 in total

1.  Inhibition of Eukaryotic Initiation Factor 2 Alpha Phosphatase Reduces Tissue Damage and Improves Learning and Memory after Experimental Traumatic Brain Injury.

Authors:  Pramod K Dash; Michael J Hylin; Kimberly N Hood; Sara A Orsi; Jing Zhao; John B Redell; Andrey S Tsvetkov; Anthony N Moore
Journal:  J Neurotrauma       Date:  2015-07-20       Impact factor: 5.269

Review 2.  Proteostasis in endoplasmic reticulum--new mechanisms in kidney disease.

Authors:  Reiko Inagi; Yu Ishimoto; Masaomi Nangaku
Journal:  Nat Rev Nephrol       Date:  2014-04-22       Impact factor: 28.314

Review 3.  Guide to drug dosage in renal failure.

Authors:  W M Bennett
Journal:  Clin Pharmacokinet       Date:  1988-11       Impact factor: 6.447

4.  Restoring endoplasmic reticulum homeostasis improves functional recovery after spinal cord injury.

Authors:  Sujata Saraswat Ohri; Michal Hetman; Scott R Whittemore
Journal:  Neurobiol Dis       Date:  2013-05-06       Impact factor: 5.996

Review 5.  Prion Properties of SOD1 in Amyotrophic Lateral Sclerosis and Potential Therapy.

Authors:  Caroline Sibilla; Anne Bertolotti
Journal:  Cold Spring Harb Perspect Biol       Date:  2017-10-03       Impact factor: 10.005

6.  Guanabenz as inhibitor of copper-containing amine oxidases.

Authors:  G Banchelli; B Bertocci; L Raimondi; G Soldani; M Del Tacca; F Buffoni
Journal:  Agents Actions       Date:  1986-04

7.  Human Keratinocyte Differentiation Requires Translational Control by the eIF2α Kinase GCN2.

Authors:  Ann E Collier; Ronald C Wek; Dan F Spandau
Journal:  J Invest Dermatol       Date:  2017-05-17       Impact factor: 8.551

8.  Inhibitors of eIF2α dephosphorylation slow replication and stabilize latency in Toxoplasma gondii.

Authors:  Christian Konrad; Sherry F Queener; Ronald C Wek; William J Sullivan
Journal:  Antimicrob Agents Chemother       Date:  2013-02-04       Impact factor: 5.191

9.  Drug withdrawal and rebound hypertension: differential action of the central antihypertensive drugs moxonidine and clonidine.

Authors:  H Rupp; B Maisch; C G Brilla
Journal:  Cardiovasc Drugs Ther       Date:  1996-06       Impact factor: 3.727

10.  Loss of Oca2 disrupts the unfolded protein response and increases resistance to endoplasmic reticulum stress in melanocytes.

Authors:  Tsing Cheng; Seth J Orlow; Prashiela Manga
Journal:  Pigment Cell Melanoma Res       Date:  2013-09-09       Impact factor: 4.693

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.